Drug/Small Molecule:
oxycodone

last updated 08/10/2011

Dutch Pharmacogenetics Working Group Guideline for oxycodone and CYP2D6

Summary

Use an alternate drug rather than oxycodone (not codeine or tramadol) for CYP2D6 poor and intermediate metabolizer patients, or be alert to insufficient pain relief. For CYP2D6 ultra metabolizer patients, use an alternate drug rather than oxycodone (not codeine or tramadol), or be alert to adverse drug events.

Annotation

The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for oxycodone based on CYP2D6 genotype (PMID:21412232). They recommend using an alternate drug for poor, intermediate and ultra metabolizer patients.

Phenotype (Genotype) Therapeutic Dose Recommendation Level of Evidence Clinical Relevance
PM (2 inactive alleles) Insufficient data to allow calculation of dose adjustment. Select alternate drug - not tramadol or codeine - or be alert to symptoms of insufficient pain relief. Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. Clinical effect (S): short-lived discomfort (< 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia > 1.5x10^9/l; leucopenia > 3.0x10^9/l; thrombocytopenia > 75x10^9/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.
IM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele) Insufficient data to allow calculation of dose adjustment. Select alternate drug - not tramadol or codeine - or be alert to symptoms of insufficient pain relief. Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. Clinical effect (NS). Kinetic effect (NS).
UM (gene duplication in absence of inactive or decreased activity alleles) Insufficient data to allow calculation of dose adjustment. Select alternate drug (NOT tramadol or codeine) or be alert to ADEs (e.g., nausea, vomiting, constipation, respiratory depression, confusion, urinary retention). Published incomplete case reports. Product information. Minor clinical effect (S): QTc prolongation (<450 ms men, <470 ms women); INR increase < 4.5. Kinetic effect (S).
Allele Type Alleles
active *1, *2, *33, *35
decreased activity *9, *10, *17, *29, *36, *41
inactive *3-*8, *11-*16, *19-*21, *38, *40, *42
  • *See Methods or PMID: 18253145 for definition of "moderate" quality.
  • S: statistically significant difference.
  • NS: not statistically significant difference.

PharmGKB gathers information regarding PGx on FDA drug labels from the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels", and from FDA-approved FDA and EMA-approved (European Medicines Agency) EMA labels brought to our attention. Excerpts from the label and downloadable highlighted label PDFs are manually curated by PharmGKB.

Please note that some drugs may have been removed from or added to the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels" without our knowledge. We periodically check the table for additions to this table and update PharmGKB accordingly.

There is currently no such list for European drug labels - we are working with the EMA to establish a list of European Public Assessment Reports (EPAR)s that contain PGx information. We are constructing this list by initially searching for drugs for which we have PGx-containing FDA drug labels - of these 44 EMA EPARs were identified and are being curated for pgx information.

We welcome any information regarding drug labels containing PGx information approved by the FDA, EMA or other Medicine Agencies around the world - please contact feedback.



PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?
GenoChip CYP2D6 (PharmGenomics, GmbH) CYP2D6*5 , rs59421388 , rs28371725 , rs5030867 , rs5030656 , rs35742686 , rs3892097 , rs5030865 , rs5030655 , rs28371706 , rs5030863 , rs1065852 , *xN (gene duplication)

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

Gene ? Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA CYP2D6 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *1XN N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *2 N/A N/A N/A
No VIP available CA VA CYP2D6 *2XN N/A N/A N/A
No VIP available CA VA CYP2D6 *3 N/A N/A N/A
No VIP available CA VA CYP2D6 *4 N/A N/A N/A
No VIP available CA VA CYP2D6 *5 N/A N/A N/A
No VIP available CA VA CYP2D6 *6 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *7 N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2D6 poor metabolizer phenotype N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs10413396 17081920G>T, 44813702G>T
G > T
Not Available
No VIP available No Clinical Annotations available VA
rs1045642 208920T>A, 208920T>C, 25171488A>G, 25171488A>T, 3435T>A, 3435T>C, 87138645A>G, 87138645A>T, ABCB1*6, ABCB1: 3435C>T, ABCB1: C3435T, ABCB1: c.3435C>T, ABCB1:3435C>T, Ile1145=, Ile1145Ile, MDR1 3435C>T, MDR1 C3435T, PGP C3435T, c.3435C>T, mRNA 3853C>T
A > T
A > G
Synonymous
Ile1145Ile
No VIP available No Clinical Annotations available VA
rs12211463 31586992T>G, 93467158T>G
T > G
Not Available
No VIP available CA VA
rs12948783 -2185C>A, -2185C>T, 3110C>A, 3110C>T, 39773552G>A, 39773552G>T, 74499400G>A, 74499400G>T
G > T
G > A
5' Flanking
No VIP available No Clinical Annotations available VA
rs13422094 1003001T>C, 22181114T>C
T > C
Not Available
No VIP available No Clinical Annotations available VA
rs1799971 -11+28644A>G, 118A>G, 154360797A>G, 34162A>G, 397A>G, 47+29103A>G, 58530254A>G, Asn133Asp, Asn40Asp, OPRM1: A118G
A > G
Missense
Asn40Asp
No VIP available No Clinical Annotations available VA
rs2032582 186947T>A, 186947T>G, 25193461A>C, 25193461A>T, 2677A, 2677G, 2677T, 2677T>A, 2677T>G, 3095G>T/A, 87160618A>C, 87160618A>T, 893 Ala, 893 Ser, 893 Thr, ABCB1*7, ABCB1: 2677G>T/A, ABCB1: 2677T/A>G, ABCB1: A893S, ABCB1: G2677T/A, ABCB1: c.2677G>T/A, ABCB1:2677G>A/T, ABCB1:2677G>T/A, ABCB1:A893T, Ala893Ser/Thr, MDR1, MDR1 G2677T/A, Ser893Ala, Ser893Thr, mRNA 3095G>T/A, p.Ala893Ser/Thr
A > C
A > T
Missense
Ser893Ala
Ser893Thr
No VIP available No Clinical Annotations available VA
rs2473967 113479335G>T, 17648792G>T
G > T
Not Available
No VIP available No Clinical Annotations available VA
rs2884129 17525149T>G, 17585149T>G
T > G
Not Available
No VIP available No Clinical Annotations available VA
rs4680 1-5G>A, 19951271G>A, 27009G>A, 3103421G>A, 322G>A, 472G>A, COMP: Val158Met, COMT:Val108Met, Val108Met, Val158Met
G > A
5' Flanking
Val158Met
No VIP available No Clinical Annotations available VA
rs7104613 116468C>T, 14019931C>T, 14079931C>T, 479+16730C>T
C > T
Not Available
No VIP available No Clinical Annotations available VA
rs7757130 113317262C>A, 17486719C>A
C > A
Not Available
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138
2D structure from PubChem
provided by PubChem

Overview

Generic Names
  • Dihydrohydroxycodeinone
  • Dihydrohydroxycondeinone
  • Dihydrone
  • Oxicodona [INN-Spanish]
  • Oxycodone Hcl
  • Oxycodone Hydrochloride
  • Oxycodonum [INN-Latin]
  • PTI-821
  • oxycodone
Trade Names
  • Combunox
  • Dihydroxycodeinone
  • Dinarkon
  • Diphydrone
  • Endocet
  • Endodan
  • Endone
  • Eubine
  • Eucodal
  • Eucodalum
  • Eukodal
  • Eutagen
  • Oxanest
  • Oxicon
  • Oxicone
  • Oxikon
  • OxyFAST
  • OxyIR
  • OxyNorm
  • Oxycodeinone
  • Oxycodon
  • Oxycon
  • Oxycontin
  • Pancodine
  • Percobarb
  • Percodan
  • Percolone
  • Remoxy
  • Roxicodone
  • Supendol
  • Supeudol
  • Tecodin
  • Tekodin
  • Thecodine
  • Thekodin
Brand Mixture Names
  • Combunox (Ibuprofen + Oxycodone Hydrochloride)
  • Endocet (Acetaminophen + Oxycodone Hydrochloride)
  • Endodan (Aspirin + Oxycodone Hydrochloride)
  • Percocet (Acetaminophen + Oxycodone Hydrochloride)
  • Percodan (Aspirin + Oxycodone Hydrochloride)
  • Rivacocet (Acetaminophen + Oxycodone Hydrochloride)
  • Roxicet (Acetaminophen + Oxycodone Hydrochloride)
  • Roxiprin (Aspirin + Oxycodone Hydrochloride)
  • Tylox (Acetaminophen + Oxycodone Hydrochloride)

PharmGKB Accession Id:
PA450741

Description

Semisynthetic derivative of codeine that acts as a narcotic analgesic more potent and addicting than codeine.

Source: Drug Bank

Indication

For the treatment of diarrhoea, pulmonary oedema and for the relief of moderate to moderately severe pain.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Oxycodone acts as a weak agonist at mu, kappa, and delta opioid receptors within the central nervous system (CNS). Oxycodone primarily affects mu-type opioid receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as oxycodone also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (kappa-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (mu and delta receptor agonist). This results in hyperpolarization and reduced neuronal excitability.

Source: Drug Bank

Pharmacology

Oxycodone, a semisynthetic opiate agonist derived from the opioid alkaloid, thebaine, is similar to other phenanthrene derivatives such as hydrocodone and morphine. Oxycodone is available in combination with aspirin or acetaminophen to control pain and restless leg and Tourette syndromes.

Source: Drug Bank

Food Interaction

Take without regard to meals. Avoid alcohol.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic

Source: Drug Bank

Protein Binding

45%

Source: Drug Bank

Absorption

Well absorbed with an oral bioavailability of 60% to 87%

Source: Drug Bank

Half-Life

4.5 hours

Source: Drug Bank

Toxicity

Symptoms of overdose include respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, bradycardia, hypotension, and death.

Source: Drug Bank

Clearance

Source: Drug Bank

Route of Elimination

Oxycodone and its metabolites are excreted primarily via the kidney.

Source: Drug Bank

Volume of Distribution

  • 2.6 L/kg

Source: Drug Bank

Chemical Properties

Chemical Formula

C18H21NO4

Source: Drug Bank

Isomeric SMILES

CN1CC[C@]23c4c5ccc(c4O[C@H]2C(=O)CC[C@]3([C@H]1C5)O)OC

Source: OpenEye

Canonical SMILES

COC1=C2O[C@H]3C(=O)CC[C@@]

Source: Drug Bank

Average Molecular Weight

315.3636

Source: Drug Bank

Monoisotopic Molecular Weight

315.147058165

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

EvidenceGene
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
ABCB1
DG No Drug Label available CA VA No VIP available No VIP available
CYP2D6
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
OPRM1
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
RHBDF2

Drug Targets

Gene Description
OPRD1 (source: Drug Bank)
OPRK1 (source: Drug Bank)
OPRM1 (source: Drug Bank)

Drug Interactions

Drug Description
oxycodone Increases the effect of the narcotic (source: Drug Bank)
oxycodone Increases the effect of the narcotic (source: Drug Bank)
oxycodone Increased risk of serotonin syndrome (source: Drug Bank)
oxycodone Increased risk of serotonin syndrome (source: Drug Bank)
oxycodone Increased risk of serotonin syndrome (source: Drug Bank)
oxycodone Increased risk of serotonin syndrome (source: Drug Bank)
oxycodone Increased risk of serotonin syndrome (source: Drug Bank)
oxycodone Increased risk of serotonin syndrome (source: Drug Bank)
oxycodone Increased risk of serotonin syndrome (source: Drug Bank)
oxycodone Increased risk of serotonin syndrome (source: Drug Bank)
oxycodone Naltrexone may precipitate a withdrawal syndrome in opioid-dependent individuals (source: Drug Bank)
oxycodone Naltrexone may precipitate a withdrawal syndrome in opioid-dependent individuals (source: Drug Bank)
cimetidine Cimetidine increases the effect of the narcotic (source: Drug Bank)
cimetidine Cimetidine increases the effect of the narcotic (source: Drug Bank)
citalopram Increased risk of serotonin syndrome (source: Drug Bank)
citalopram Increased risk of serotonin syndrome (source: Drug Bank)
escitalopram Increased risk of serotonin syndrome (source: Drug Bank)
escitalopram Increased risk of serotonin syndrome (source: Drug Bank)
fluoxetine Increased risk of serotonin syndrome (source: Drug Bank)
fluoxetine Increased risk of serotonin syndrome (source: Drug Bank)
fluvoxamine Increased risk of serotonin syndrome (source: Drug Bank)
fluvoxamine Increased risk of serotonin syndrome (source: Drug Bank)
naltrexone Naltrexone may precipitate a withdrawal syndrome in opioid-dependent individuals (source: Drug Bank)
naltrexone Naltrexone may precipitate a withdrawal syndrome in opioid-dependent individuals (source: Drug Bank)
paroxetine Increased risk of serotonin syndrome (source: Drug Bank)
paroxetine Increased risk of serotonin syndrome (source: Drug Bank)
sertraline Increased risk of serotonin syndrome (source: Drug Bank)
sertraline Increased risk of serotonin syndrome (source: Drug Bank)
oxycodone Increased risk of serotonin syndrome (source: Drug Bank)
oxycodone Increased risk of serotonin syndrome (source: Drug Bank)
oxycodone The CNS depressants, Triprolidine and Oxycodone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. (source: Drug Bank)
oxycodone The CNS depressants, Triprolidine and Oxycodone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to oxycodone: 25

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P450-mediated drug metabolism in the brain. Journal of psychiatry & neuroscience : JPN. 2012. Miksys Sharon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2D6 genotype dependent oxycodone metabolism in postoperative patients. PloS one. 2013. Stamer Ulrike M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study. European journal of clinical pharmacology. 2012. Andreassen Trine Naalsund, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Multiple Loci modulate opioid therapy response for cancer pain. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. Galvan Antonella, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs. Regulatory toxicology and pharmacology : RTP. 2011. Volpe Donna A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics: From Bench to Byte- An Update of Guidelines. Clinical pharmacology and therapeutics. 2011. Swen J J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Lack of Association of OPRM1 and ABCB1 Single-Nucleotide Polymorphisms to Oxycodone Response in Postoperative Pain. Journal of clinical pharmacology. 2011. Zwisler Stine T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. Pharmacogenomics. 2011. Meyer Markus R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes. Fundamental & clinical pharmacology. 2010. Zwisler Stine T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. British journal of pharmacology. 2010. Samer C F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The influence of ondansetron on the analgesic effect of acetaminophen after laparoscopic hysterectomy. Clinical pharmacology and therapeutics. 2010. Jokela R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Personalized therapy in pain management: where do we stand?. Pharmacogenomics. 2010. Stamer Ulrike M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia. Acta anaesthesiologica Scandinavica. 2010. Zwisler S T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management. Pharmacogenomics. 2009. Jannetto Paul J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenetics and genomics. 2009. Lötsch Jörn, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. Basic & clinical pharmacology & toxicology. 2009. Zwisler Stine T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry. 2008. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Complicated pain management in a CYP450 2D6 poor metabolizer. Pain practice : the official journal of World Institute of Pain. 2007. Foster Adriana, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Progress in neuro-psychopharmacology & biological psychiatry. 2006. Susce Margaret T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clinical pharmacology and therapeutics. 2006. Lalovic Bojan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. Journal of clinical psychopharmacology. 2003. de Leon Jose, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2003. Davis Mellar P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Med-psych drug-drug interactions update. Psychosomatics. 2002. Armstrong Scott C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. Journal of pain and symptom management. 1996. Maddocks I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model. The Journal of pharmacology and experimental therapeutics. 1994. Cleary J, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0406-0552-01
DrugBank:
DB00497
ChEBI:
7852
KEGG Compound:
C08018
KEGG Drug:
D05312
PubChem Compound:
5284603
PubChem Substance:
149393
46508908
Drugs Product Database (DPD):
2262983
ChemSpider:
4447649
Therapeutic Targets Database:
DAP000283
FDA Drug Label at DailyMed:
928227bf-89c5-4c64-9823-0e84cc669388

Clinical Trials

These are trials that mention oxycodone and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.